Artivion, Inc. (AORT)
USD 27.79
(-3.84%)
USD 27.79
(-3.84%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 38.14 Million USD | 47.43% |
| 2022 | 19.73 Million USD | 153.93% |
| 2021 | 25.04 Million USD | 2224.79% |
| 2020 | 20.23 Million USD | -102.88% |
| 2019 | 39.98 Million USD | 75.91% |
| 2018 | 30.2 Million USD | 11.31% |
| 2017 | 18.17 Million USD | -37.65% |
| 2016 | 25.28 Million USD | 203.38% |
| 2015 | 11.21 Million USD | -68.96% |
| 2014 | 14.86 Million USD | 3.8% |
| 2013 | 19.66 Million USD | 10.17% |
| 2012 | 17.86 Million USD | 7.84% |
| 2011 | 16.56 Million USD | -13.03% |
| 2010 | 11.39 Million USD | -28.83% |
| 2009 | 18.7 Million USD | 36.5% |
| 2008 | 18.15 Million USD | 3.48% |
| 2007 | 12.75 Million USD | 764.79% |
| 2006 | 3.64 Million USD | 110.28% |
| 2005 | -14.58 Million USD | 8.14% |
| 2004 | -16.08 Million USD | 31.14% |
| 2003 | -23.71 Million USD | 27.88% |
| 2002 | -34.54 Million USD | -283.43% |
| 2001 | 17.06 Million USD | 39.3% |
| 2000 | 13.03 Million USD | 0.91% |
| 1999 | 10.61 Million USD | 65.56% |
| 1998 | 10.3 Million USD | -32.46% |
| 1997 | 11.4 Million USD | 60.56% |
| 1996 | 7.2 Million USD | 86.84% |
| 1995 | 4.1 Million USD | 65.22% |
| 1994 | 2.5 Million USD | 64.29% |
| 1993 | 1.4 Million USD | -22.22% |
| 1992 | 1.8 Million USD | 1000.0% |
| 1991 | - USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 31.22 Million USD | 29.17% |
| 2024 Q2 | 14.15 Million USD | 3.09% |
| 2023 Q2 | -4.78 Million USD | -264.34% |
| 2023 Q4 | 3.17 Million USD | 7.78% |
| 2023 FY | - USD | 47.43% |
| 2023 Q1 | 2.91 Million USD | -66.34% |
| 2023 Q3 | 2.94 Million USD | 161.52% |
| 2022 FY | - USD | 153.93% |
| 2022 Q1 | 7.4 Million USD | 160.68% |
| 2022 Q2 | 6.41 Million USD | -13.28% |
| 2022 Q3 | -2.2 Million USD | -134.41% |
| 2022 Q4 | 8.64 Million USD | 491.62% |
| 2021 Q1 | 5.54 Million USD | 19.87% |
| 2021 Q2 | 8.66 Million USD | 56.27% |
| 2021 Q3 | 2.13 Million USD | -75.42% |
| 2021 Q4 | -12.19 Million USD | -672.54% |
| 2021 FY | - USD | 2224.79% |
| 2020 FY | - USD | -102.88% |
| 2020 Q3 | 5.93 Million USD | 63.5% |
| 2020 Q1 | -4.74 Million USD | -191.76% |
| 2020 Q2 | 3.63 Million USD | 176.47% |
| 2020 Q4 | 4.62 Million USD | -22.06% |
| 2019 Q2 | 6.55 Million USD | 191.89% |
| 2019 FY | - USD | 75.91% |
| 2019 Q1 | 2.24 Million USD | -9.0% |
| 2019 Q3 | 2.56 Million USD | -60.87% |
| 2019 Q4 | 5.17 Million USD | 101.83% |
| 2018 Q2 | 8.69 Million USD | 367.63% |
| 2018 Q4 | 2.46 Million USD | -77.05% |
| 2018 Q3 | 10.74 Million USD | 23.51% |
| 2018 FY | - USD | 11.31% |
| 2018 Q1 | -3.25 Million USD | -6870.83% |
| 2017 Q4 | 48 Thousand USD | -98.5% |
| 2017 Q3 | 3.2 Million USD | -35.64% |
| 2017 FY | - USD | -37.65% |
| 2017 Q2 | 4.97 Million USD | 5.6% |
| 2017 Q1 | 4.71 Million USD | 3.67% |
| 2016 Q2 | 6.82 Million USD | 765.74% |
| 2016 FY | - USD | 203.38% |
| 2016 Q1 | 788 Thousand USD | -83.71% |
| 2016 Q4 | 4.54 Million USD | -40.44% |
| 2016 Q3 | 7.63 Million USD | 11.87% |
| 2015 Q3 | 3.95 Million USD | 359.47% |
| 2015 Q2 | 861 Thousand USD | 149.4% |
| 2015 Q4 | 4.83 Million USD | 22.27% |
| 2015 FY | - USD | -68.96% |
| 2015 Q1 | -1.74 Million USD | -153.63% |
| 2014 Q4 | 3.25 Million USD | -28.46% |
| 2014 Q3 | 4.54 Million USD | 104.46% |
| 2014 Q1 | 1.79 Million USD | 128.18% |
| 2014 Q2 | 2.22 Million USD | 23.58% |
| 2014 FY | - USD | 3.8% |
| 2013 Q1 | 4.54 Million USD | 101.02% |
| 2013 Q2 | 4.27 Million USD | -5.96% |
| 2013 FY | - USD | 10.17% |
| 2013 Q4 | -6.38 Million USD | -236.12% |
| 2013 Q3 | 4.68 Million USD | 9.61% |
| 2012 Q4 | 2.26 Million USD | -23.3% |
| 2012 Q3 | 2.94 Million USD | -49.43% |
| 2012 Q2 | 5.83 Million USD | 93.79% |
| 2012 Q1 | 3 Million USD | -30.88% |
| 2012 FY | - USD | 7.84% |
| 2011 Q1 | 3.47 Million USD | -20.76% |
| 2011 Q4 | 4.35 Million USD | 12.8% |
| 2011 Q2 | 3.75 Million USD | 8.09% |
| 2011 Q3 | 3.85 Million USD | 2.8% |
| 2011 FY | - USD | -13.03% |
| 2010 Q4 | 4.38 Million USD | 75.46% |
| 2010 Q1 | 2.68 Million USD | -42.9% |
| 2010 Q2 | 5.83 Million USD | 117.01% |
| 2010 Q3 | 2.49 Million USD | -57.16% |
| 2010 FY | - USD | -28.83% |
| 2009 Q1 | 4.55 Million USD | 10.07% |
| 2009 Q3 | 4.29 Million USD | 101031.54% |
| 2009 FY | - USD | 36.5% |
| 2009 Q4 | 4.7 Million USD | 9.7% |
| 2009 Q2 | 4242.00 USD | -99.91% |
| 2008 Q3 | 5.13 Million USD | -4.06% |
| 2008 Q1 | 3.77 Million USD | -3.18% |
| 2008 FY | - USD | 3.48% |
| 2008 Q2 | 5.34 Million USD | 41.76% |
| 2008 Q4 | 4.13 Million USD | -19.32% |
| 2007 FY | - USD | 764.79% |
| 2007 Q4 | 3.89 Million USD | 62.6% |
| 2007 Q3 | 2.39 Million USD | -44.59% |
| 2007 Q2 | 4.32 Million USD | 59.03% |
| 2007 Q1 | 2.71 Million USD | 172.05% |
| 2006 FY | - USD | 110.28% |
| 2006 Q4 | -3.77 Million USD | -213.03% |
| 2006 Q3 | 3.33 Million USD | 50.0% |
| 2006 Q2 | 2.22 Million USD | 993.98% |
| 2006 Q1 | -249 Thousand USD | 77.89% |
| 2005 FY | - USD | 8.14% |
| 2005 Q1 | -9000.00 USD | 99.67% |
| 2005 Q3 | -2.6 Million USD | 76.84% |
| 2005 Q4 | -1.12 Million USD | 56.79% |
| 2005 Q2 | -11.25 Million USD | -124933.33% |
| 2004 Q4 | -2.69 Million USD | 41.83% |
| 2004 Q2 | -3.32 Million USD | 41.35% |
| 2004 Q1 | -5.66 Million USD | -1.76% |
| 2004 FY | - USD | 31.14% |
| 2004 Q3 | -4.63 Million USD | -39.44% |
| 2003 FY | - USD | 27.88% |
| 2003 Q4 | -5.53 Million USD | -29.66% |
| 2003 Q3 | -4.2 Million USD | 70.46% |
| 2003 Q1 | 728 Thousand USD | 111.88% |
| 2003 Q2 | -14.7 Million USD | -2171.37% |
| 2002 Q4 | -6.21 Million USD | 76.87% |
| 2002 Q3 | -26.96 Million USD | -257.37% |
| 2002 Q2 | -7.12 Million USD | -225.0% |
| 2002 Q1 | 5.77 Million USD | 24.18% |
| 2002 FY | - USD | -283.43% |
| 2001 Q1 | 4.09 Million USD | 44.87% |
| 2001 FY | - USD | 39.3% |
| 2001 Q4 | 3.86 Million USD | -6.06% |
| 2001 Q3 | 4.78 Million USD | 13.27% |
| 2001 Q2 | 4.33 Million USD | 5.74% |
| 2000 FY | - USD | 0.91% |
| 2000 Q4 | 2.92 Million USD | -28.23% |
| 2000 Q1 | 2.88 Million USD | 42.24% |
| 2000 Q2 | 3.36 Million USD | 14.01% |
| 2000 Q3 | 3.9 Million USD | 20.3% |
| 1999 Q2 | 3.19 Million USD | 61.11% |
| 1999 Q1 | 2.3 Million USD | 200.0% |
| 1999 Q4 | 2.01 Million USD | -32.77% |
| 1999 Q3 | 3 Million USD | 3.45% |
| 1999 FY | - USD | 65.56% |
| 1998 FY | - USD | -32.46% |
| 1998 Q1 | 3.3 Million USD | -2.94% |
| 1998 Q2 | 3 Million USD | 3.03% |
| 1998 Q3 | 1.6 Million USD | -52.94% |
| 1998 Q4 | 2 Million USD | -62.5% |
| 1997 Q1 | 2.2 Million USD | 46.67% |
| 1997 FY | - USD | 60.56% |
| 1997 Q3 | 2.7 Million USD | -12.9% |
| 1997 Q4 | 3.4 Million USD | 25.93% |
| 1997 Q2 | 3.1 Million USD | 40.91% |
| 1996 Q4 | 1.5 Million USD | -37.5% |
| 1996 Q3 | 2.4 Million USD | 33.33% |
| 1996 Q2 | 1.8 Million USD | 50.0% |
| 1996 Q1 | 1.4 Million USD | 33.33% |
| 1996 FY | - USD | 86.84% |
| 1995 Q2 | 1.1 Million USD | 37.5% |
| 1995 Q3 | 1.1 Million USD | 0.0% |
| 1995 Q4 | 900 Thousand USD | -18.18% |
| 1995 FY | - USD | 65.22% |
| 1995 Q1 | 800 Thousand USD | 60.0% |
| 1994 Q2 | 700 Thousand USD | 40.0% |
| 1994 Q4 | 500 Thousand USD | -37.5% |
| 1994 FY | - USD | 64.29% |
| 1994 Q1 | 500 Thousand USD | 66.67% |
| 1994 Q3 | 800 Thousand USD | 14.29% |
| 1993 Q2 | 500 Thousand USD | -91.49% |
| 1993 FY | - USD | -22.22% |
| 1993 Q1 | 4.7 Million USD | 133.81% |
| 1993 Q3 | 500 Thousand USD | 25.0% |
| 1993 Q4 | 300 Thousand USD | -40.0% |
| 1992 FY | - USD | 1000.0% |
| 1992 Q1 | 4.5 Million USD | 138.79% |
| 1992 Q3 | 5.3 Million USD | 0.0% |
| 1992 Q2 | 5.3 Million USD | 17.78% |
| 1992 Q4 | -13.9 Million USD | -362.26% |
| 1991 Q1 | 2.9 Million USD | 0.0% |
| 1991 Q2 | 3.6 Million USD | 24.14% |
| 1991 Q3 | 4.5 Million USD | 25.0% |
| 1991 Q4 | -11.6 Million USD | -357.78% |
| 1991 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 99.635% |
| Allurion Technologies Inc. | -69.03 Million USD | 155.253% |
| Avanos Medical, Inc. | 53.2 Million USD | 28.305% |
| Butterfly Network, Inc. | -124.84 Million USD | 130.552% |
| Butterfly Network, Inc. | -124.84 Million USD | 130.552% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 106.271% |
| Boston Scientific Corporation | 3.45 Billion USD | 98.895% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 357.056% |
| CONMED Corporation | 182.18 Million USD | 79.064% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 97.842% |
| Paragon 28, Inc. | -36.61 Million USD | 204.173% |
| Glaukos Corporation | -82.11 Million USD | 146.449% |
| Globus Medical, Inc. | 418.23 Million USD | 90.88% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 323.576% |
| Integer Holdings Corporation | 282.05 Million USD | 86.477% |
| Medtronic plc | 9.05 Billion USD | 99.579% |
| Nevro Corp. | -78.31 Million USD | 148.706% |
| Owlet, Inc. | -27.48 Million USD | 238.754% |
| Penumbra, Inc. | 111.99 Million USD | 65.943% |
| Vicarious Surgical Inc. | -69.19 Million USD | 155.125% |
| Smith & Nephew plc | 979 Million USD | 96.104% |
| Sonendo, Inc. | -54.76 Million USD | 169.643% |
| STERIS plc | 1.41 Billion USD | 97.299% |
| Stryker Corporation | 5.16 Billion USD | 99.261% |
| Vapotherm, Inc. | -34.35 Million USD | 211.017% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 98.442% |